Back to results

Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma (BVD)

Primary Purpose

Multiple Myeloma

Status

Completed

Phase

Phase 2

Locations

France

Study Type

Interventional

Intervention

Bendamustine, Velcade and Dexamethasone

About this trial

This is an interventional treatment trial for Multiple Myeloma focused on measuring Multiple Myeloma, Elderly patients, first relapse, refractory to first line therapy, Bendamustine Velcade Dexamethasone Association

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Symptomatic multiple myeloma (MM) patient at the time of diagnosis (but not necessarily at the time of relapse), according to International Myeloma Working Group criteria.
Patient having received conventional chemotherapy in 1st line treatment because of age 65 years or over, or younger than 65 years and ineligible to high-dose therapy plus stem cell transplantation.
Measurable disease (≥10g/L monoclonal gammapathy and/or ≥ 200 mg/24h proteinuria or involved serum free light chain ≥ 100mg/L with abnormal FLC ratio < 0.26 or > 1.65)
Patient in 1st relapse or refractory to 1st line therapy. Relapse is defined by M-component increase of ≥25% from baseline, in serum and/or urine (the absolute increase in serum must be ≥ 5 g/l - the absolute increase of BJ proteins in urine must be ≥200 mg/24 h). (It is recommended to treat only symptomatic or rapidly evolutive relapses)
Life expectancy of at least 3 months
ECOG performance status <= 2 at study entry
Laboratory test results within these ranges:
Absolute neutrophil count >= 1.5 x 109/L
Platelet count >= 100 x 109/L
Serum creatinine <= 250 umol/l
AST (SGOT) and ALT (SGPT) <= 3 x ULN
Disease free of prior malignancies for >= 5 years, with exception of curatively treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast
Able to adhere to the study visit schedule and other protocol requirements
Using effective contraceptive methods during and for 6 months after study treatment (for fertile men, women of childbearing potential).
Provision of informed consent.
A period of at least 15 days must be respected between the last treatment of myeloma and the beginning of the study.

Exclusion Criteria:

Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form.
Any comorbidity which places the subject at unacceptable risk if he/she were to participate in the study.
Patients treated with high-dose therapy plus stem cell transplantation in 1st line therapy
Any prior use of bortezomib (Velcade) or bendamustine (Ribomustin)
Concurrent use of other anti-cancer agents or treatments other than those stated in this treatment plan
Use of any other experimental drug or therapy within 28 days prior to the start of study treatment.
Known hypersensitivity to the study drugs
Positive HIV serology, positive hepatitis C serology, active infection hepatitis A, active infection hepatitis B.
Severe cardiovascular disorders within 12 months prior to the start of study treatment (e.g. myocardial infarct, ischemic episodes, arrhythmias)
Previous major surgery less than 30 days before start of treatment
Active infection,
Pregnant or lactating women.

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

BVD

Arm Description

Bendamustine, Velcade and Dexamethasone

Outcomes

Primary Outcome Measures

To assess of the overall response rate (complete response (CR) + partial response (PR))

Secondary Outcome Measures

Time to best response

Progression-free survival

Time to progression

Overall survival

Rate of additional response

Toxicity/Adverse events

Full Information

NCT ID

NCT01045681

First Posted

January 7, 2010

Last Updated

December 3, 2020

Sponsor

Intergroupe Francophone du Myelome

1. Study Identification

Unique Protocol Identification Number

NCT01045681

Brief Title

Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma

Acronym

BVD

Official Title

A Phase II Study of Bendamustine, Velcade and Dexamethasone (BVD) in the Treatment of Elderly Patients (>= 65 Years) With Multiple Myeloma in 1st Relapse or Refractory to 1st Line Therapy

Study Type

Interventional

2. Study Status

Record Verification Date

March 2012

Overall Recruitment Status

Completed

Study Start Date

March 3, 2010 (Actual)

Primary Completion Date

March 28, 2013 (Actual)

Study Completion Date

March 28, 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Intergroupe Francophone du Myelome

4. Oversight

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The present trial is designed as a phase II study that aims at estimating the efficacy of the combination of bendamustine, bortezomib and dexamethasone in relapsed/refractory multiple myeloma (MM). The response rate, i.e. the rate of the patients achieving a Complete Response or Partial Response at cycle 4, divided by the total intent to treat patient number is chosen as primary efficacy endpoint. The estimation of the efficacy rate is to be based on an explorative pilot study, since immediate embarking on a large-scale comparative efficacy trial would not be acceptable from the point of view of resources. Moreover, this would induce ethical objections, as it does not seem to be justifiable to expose a large number of patients to an experimental approach without sufficient exploratory indications of an improved risk-benefit ratio.

Detailed Description

After relapse or after early progression on first-line treatment, the prognosis of multiple myeloma (MM) patients is unfavourable, and the search for new treatment regimens, including drugs with novel mechanisms of action is essential. Bendamustine and bortezomib have shown high activity boch in first-line regimens and pre-treated patients. The novel mechanism of action of the proteasome inhibitor and the non-cross resistance of bendamustine to other alkylating agents established in the first-line treatment of multiple myeloma seem to recommend a combination of the two drugs for salvage therapy (second-line regimen). Finally, the promising response data in a series of relapsing MM patients treated with bendamustine, bortezomib and prednisone support this assumption, as well as the feasibility and tolerability of the combination. In summary, there is some evidence for a favorable risk/benefit ratio for the combination of bendamustine, bortezomib and a corticoid drug, warranting the exploration in a larger, prospectively designed multicenter phase II study.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Multiple Myeloma

Keywords

Multiple Myeloma, Elderly patients, first relapse, refractory to first line therapy, Bendamustine Velcade Dexamethasone Association

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 2

Interventional Study Model

Single Group Assignment

Masking

None (Open Label)

Allocation

N/A

Enrollment

75 (Actual)

8. Arms, Groups, and Interventions

Arm Title

BVD

Arm Type

Experimental

Arm Description

Bendamustine, Velcade and Dexamethasone

Intervention Type

Drug

Intervention Name(s)

Bendamustine, Velcade and Dexamethasone

Other Intervention Name(s)

Robimustin : Bendamustine, Velcade : Bortezomib, Dexamethasone

Intervention Description

Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade

Primary Outcome Measure Information:

Title

To assess of the overall response rate (complete response (CR) + partial response (PR))

Time Frame

After four 28-day consecutives cycles

Secondary Outcome Measure Information:

Title

Time to best response

Time Frame

the time from treatment start to the first detection of the best response category, calculated for all patients, which are not primarily refractory

Title

Progression-free survival

Time Frame

The time form the initial dose of chemotherapy to the time of disease progression or death, or to the date of last assessment without any such event (censored observation)

Title

Time to progression

Time Frame

The time from baseline to the development of progressive disease

Title

Overall survival

Time Frame

The time interval from initial dose to the date of death or last observation (censored)

Title

Rate of additional response

Time Frame

Following 2 consolidation cycles and following 6 maintenance cycles

Title

Toxicity/Adverse events

Time Frame

From the time a signed and dated informed consent form is obtained until 60 days following the lase dose of study medication or until the start of a new subsequent antimyeloma therapy

10. Eligibility

Sex

All

Minimum Age & Unit of Time

65 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Symptomatic multiple myeloma (MM) patient at the time of diagnosis (but not necessarily at the time of relapse), according to International Myeloma Working Group criteria. Patient having received conventional chemotherapy in 1st line treatment because of age 65 years or over, or younger than 65 years and ineligible to high-dose therapy plus stem cell transplantation. Measurable disease (≥10g/L monoclonal gammapathy and/or ≥ 200 mg/24h proteinuria or involved serum free light chain ≥ 100mg/L with abnormal FLC ratio < 0.26 or > 1.65) Patient in 1st relapse or refractory to 1st line therapy. Relapse is defined by M-component increase of ≥25% from baseline, in serum and/or urine (the absolute increase in serum must be ≥ 5 g/l - the absolute increase of BJ proteins in urine must be ≥200 mg/24 h). (It is recommended to treat only symptomatic or rapidly evolutive relapses) Life expectancy of at least 3 months ECOG performance status <= 2 at study entry Laboratory test results within these ranges: Absolute neutrophil count >= 1.5 x 109/L Platelet count >= 100 x 109/L Serum creatinine <= 250 umol/l AST (SGOT) and ALT (SGPT) <= 3 x ULN Disease free of prior malignancies for >= 5 years, with exception of curatively treated basal cell, squamous cell carcinoma of the skin, or carcinoma "in situ" of the cervix or breast Able to adhere to the study visit schedule and other protocol requirements Using effective contraceptive methods during and for 6 months after study treatment (for fertile men, women of childbearing potential). Provision of informed consent. A period of at least 15 days must be respected between the last treatment of myeloma and the beginning of the study. Exclusion Criteria: Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the informed consent form. Any comorbidity which places the subject at unacceptable risk if he/she were to participate in the study. Patients treated with high-dose therapy plus stem cell transplantation in 1st line therapy Any prior use of bortezomib (Velcade) or bendamustine (Ribomustin) Concurrent use of other anti-cancer agents or treatments other than those stated in this treatment plan Use of any other experimental drug or therapy within 28 days prior to the start of study treatment. Known hypersensitivity to the study drugs Positive HIV serology, positive hepatitis C serology, active infection hepatitis A, active infection hepatitis B. Severe cardiovascular disorders within 12 months prior to the start of study treatment (e.g. myocardial infarct, ischemic episodes, arrhythmias) Previous major surgery less than 30 days before start of treatment Active infection, Pregnant or lactating women.

Overall Study Officials: